Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

This study has been completed.
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00417833
First received: January 3, 2007
Last updated: October 17, 2008
Last verified: October 2008
  Purpose

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).

Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.


Condition Intervention Phase
Diabetic Proliferative Retinopathy
Vascular Vein Oclussion
Choroidal Neovascularization
Drug: Intravitreal Bevacizumab
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Study Start Date: December 2005
Estimated Study Completion Date: July 2006
  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization
  • Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment
  • Completely studies

Exclusion Criteria:

Complications

  • Tractional Detachment
  • Endophthalmitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00417833

Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Myrian L Hernández, MD Asociación para Evitar la Ceguera en México
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00417833     History of Changes
Other Study ID Numbers: APEC-0017
Study First Received: January 3, 2007
Last Updated: October 17, 2008
Health Authority: México: Secretaria de Salud

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on September 30, 2014